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Background—Minimally invasive inguinal lymph node dissection (MILND) is a novel approach
to inguinal lymphadenectomy. SAFE-MILND (NCT01500304) is a multicenter, phase I/II clinical
trial evaluating the safety and feasibility of MILND for patients with melanoma in a group of
surgeons newly adopting the procedure.
Methods—Twelve melanoma surgeons from 10 institutions without any previous MILND
experience, enrolled patients into a prospective study after completing specialized training

Reprints: James W. Jakub, MD, Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905.
jakub.james@mayo.edu.
The authors report no conflicts of interest.

Jakub et al.

Page 2

Author Manuscript

including didactic lectures, participating in a hands-on cadaveric laboratory, and being provided an
instructional DVD of the procedure. Complications and adverse postoperative events were graded
using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events
Version 4.0.
Results—Eighty-seven patients underwent a MILND. Seventy-seven cases (88.5%) were
completed via a minimally invasive approach. The median total inguinal lymph nodes
pathologically examined (SLN + MILND) was 12.0 (interquartile range 8.0, 14.0). Overall, 71%
of patients suffered an adverse event (AE); the majority of these were grades 1 and 2, with 26% of
patients experiencing a grade 3 AE. No grade 4 or 5 AEs were observed.
Conclusions—After a structured training program, high-volume melanoma surgeons adopted a
novel surgical technique with a lymph node retrieval rate that met or exceeded current oncologic
guidelines and published benchmarks, and a favorable morbidity profile.
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The most frequent site of metastatic spread of melanoma is to the regional lymph nodes. In
breast cancer, nodal evaluation serves primarily as a staging procedure, and complete
axillary lymph node dissection offers little, if any, benefit for those with clinically occult
disease, especially in those receiving standard adjuvant therapies.1 In contrast, with
melanoma, even isolated tumor cells within the lymph nodes are considered clinically
relevant and staged as node-positive.2 The goal of a lymphadenectomy is to remove and
pathologically analyze lymph nodes for regional control, staging, directing adjuvant therapy
decisions, and in a subset of patients, potentially improve survival.
Lymphadenectomy is the current standard for patients presenting with clinical nodal disease
or a positive sentinel lymph node (SLN). Unfortunately, inguinal lymph node dissection is
associated with significant morbidity. Three prospective trials have reported postoperative
morbidity in approximately 70% of patients undergoing inguinal lymph node dissection
through a conventional open approach,3–5 including wound infection, wound dehiscence,
and seroma formation. Numerous interventions have been attempted to minimize these
complications, but these have not been successful.6–8
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Minimally invasive inguinal lymph node dissection (MILND) is a novel approach to an
inguinal lymphadenectomy. MILND is a 3-trocar technique that respects the anatomic
boundaries of the femoral triangle, similar to its open predecessor. The procedure was first
described in a cadaveric model and 1 patient in 2003,9 and in 2006, a series of 7 patients
with penile carcinoma was published.10 Delman et al11 modified the technique to be
appropriate for patients with melanoma, and demonstrated the feasibility of this approach in
a series of 5 patients, presented at the 2009 Society of Surgical Oncology meeting.
Institutional series of 13 and 40 cases, respectively, have shown that the number of lymph
nodes pathologically reported with MILND is comparable with the conventional open
approach, yet short-term morbidity is decreased.12,13
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The Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection trial
(SAFE-MILND, NCT01500304) is a multicenter, phase I/II clinical trial designed to
evaluate the safety and feasibility of MILND for patients with melanoma in a group of
surgeons newly adopting the procedure. Herein, we report our findings, including the
number of lymph nodes pathologically identified, adverse events (AEs), length of stay
(LOS), and drain-days, and compare this with published reports for the conventional open
approach.

METHODS

Author Manuscript

A select group of melanoma surgeons practicing in the United States, who performed at least
6 open inguinal lymph node dissections per year and had had no previous MILND
experience, were identified and invited to participate in a structured training program to
learn the innovative procedure. After obtaining institutional approval, each surgeon
prospectively enrolled patients and submitted all data to a central site.
Training
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All participating surgeons came to Mayo Clinic, Rochester, MN, for instructional training,
which included viewing an instructional video, which was created by Mayo Clinic Media
Support services, depicting the procedure in high-quality graphic detail, and adhering to
effective adult learning principles. The 20-minute video included a 3-dimensional animated
component of the relevant anatomy with key steps of the procedure outlined and visually
depicted, and also a series of edited operative cases, highlighting the critical aspects of the
procedure. The video can be seen at http://medprofvideos.mayoclinic.org/videos/minimallyinvasive-inguinal-lymph-node-dissection-milnd. All attendees then participated in a handson cadaveric laboratory. During this training workshop, trainees performed MILND in a
controlled environment under instructional supervision. During the hands-on cadaveric
dissection, each participant functioned as an assistant for 1 case and as a surgeon for 1 case.
Participants were provided a DVD copy of the educational video to allow them to review the
operation in detail as needed after completion of the workshop.
Inclusion/Exclusion Criteria
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Patients at least 18 years of age with melanoma, who were advised to undergo an inguinal
lymphadenectomy secondary to clinical disease or a positive SLN biopsy, were eligible.
Patients were not eligible for enrollment if they had a prior inguinal lymphadenectomy in the
ipsilateral leg, prior radiation to the ipsilateral groin, or direct ulceration or invasion of the
overlying skin. Patients with American Society of Anesthesiologists (ASA) class 4 or
greater were also excluded. The decision to perform a combined pelvic lymphadenectomy
was at the discretion of the operating surgeon.
Enrollment Scheme
A 2-stage enrollment scheme was used when a surgeon performed 5 cases and submitted
surgical and pathologic data, and also 30 and/or 90-day postoperative visit results. The
principal investigator reviewed these materials. If at most 4 lymph nodes were found on
pathologic review in 3 or more of the cases, 2 or more cases converted to an open procedure,
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or 3 or more cases developed a grade 3+ adverse (excluding seroma or lymphedema), the
surgeon would not be allowed to enroll additional cases.
Complications
Complications and adverse postoperative events were graded using the NCI Common
Terminology Criteria for Adverse Events Version 4.0 (CTCAE v 4.0). Data collected
included transfusion in the postoperative period, days the drain was in place, replacement of
drains, duration of hospital stay, wound infections, wound dehiscence, seromas, arterial or
venous injury, sensory and/or motor neuropathy, hemorrhagic and venous thromboembolic
events, and other AEs in the 30 to 90-day follow-up period. Complications were captured on
intent-to-treat basis.
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Preoperative and postoperative limb volume measurements were obtained on both the
operative and nonoperative lower extremity. Estimated leg volume recording by serial
circumferential measurements at 4-cm intervals bilaterally from the heel to the groin was
encouraged, but recording by other institutional established protocols was allowed including
perometer and water displacement methods. The volumetric definition of lymphedema was
an interlimb difference of at least 5% postop compared with baseline. This is adapted from
the CTCAE v 3.0 criterion,14 and has been utilized to identify the presence of lymphedema
in prospective cohorts15,16 and randomized controlled trials.17,18 Patients undergoing a
bilateral MILND procedure were eligible to be enrolled in the protocol, but were excluded
from lymphedema calculations. Stopping rules were established including termination of the
study, if 2 of the first 6 surgeons to complete cohort 1 lost enrollment privileges, or if, at any
point in the study, 30% or more of the participating surgeons were not allowed to enroll
additional patients as defined under the enrollment scheme above. A data safety monitoring
board was established and monitored the trial.
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Statistical Analysis
Descriptive statistics were used to summarize patient and surgical characteristics such as
patient sex, age, body mass index (BMI), smoking history, limb volume, indication for
inguinal node dissection (clinical nodal disease or SLN positivity), the number of lymph
nodes pathologically identified, number of total positive inguinal lymph nodes, if deep
pelvic lymphadenectomy was performed, and blood loss.

RESULTS
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Twelve surgeons from 10 institutions enrolled 88 patients between June 2012 and September
2014. None of the surgeons discontinued participation due to unacceptable outcomes as
detailed in the “Methods” section. One patient withdrew preoperatively and 87 operative
cases made up the study group. The median MILND procedures performed per participating
surgeon were 6, with a range of 1 to 24. Mean patient age was 55.8, with 52 females
(59.8%) and 35 males (40.2%). All patients had either 30 or 90-day follow-up; 83 patients
had 30-day and 49 patients had 90-day follow-up, with 44 having both. The median length
of follow-up was 72 days from surgery, with a range of 11 to 151.
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The majority of patients (65, 74.7%) underwent a complete lymph node dissection
secondary to a positive SLN, and 22 patients (25.3%) presented with clinical inguinal nodal
disease. The median number of lymph nodes pathologically identified after the MILND was
10, with an interquartile range (IQR) of 6 to 13. The median total inguinal lymph nodes
pathologically examined (SLN + MILND) was 12.0 (IQR 8.0, 14.0). Figure 1 is a histogram,
which visually depicts the distribution of the number of lymph nodes pathologically
identified for the cases completed via a minimally invasive approach. There was 44 (50.6%)
cases with at least 1 MILND lymph node involved with metastatic disease, and in the other
43 (49.4%), the complete lymphadenectomy specimens were negative (range of positive
lymph nodes at inguinal dissection 0–7, not counting prior positive SLNs). In the 65 patients
whose indication for a completion lymphadenectomy was a positive SLN, 22 (34%) had
further nodal disease. Seven patients underwent a combined pelvic lymphadenectomy and 3
(42.9%) had positive pelvic nodal disease.
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Among the 87 patients in whom MILND was attempted, 10 (11.5%) were converted to an
open procedure. The median hospital LOS was 1 day (IQR 1–2) for those successfully
completed via a MILND and 3 days (IQR 2–4) for those converted to an open procedure.
AEs are listed in Table 1 and are based on intent-to-treat analysis. Overall, 71% of patients
suffered an AE; the majority of these were grades 1 or 2, with 26% of patients experiencing
a grade 3 AE. No grade 4 or 5 AEs were observed. Hemorrhagic events included anemia (8),
venous injury (2), intraoperative hemorrhage (1), and postop hematoma (2). Only 1 patient
required a blood transfusion and none required a take-back for bleeding. Two patients had a
skin injury that required debridement or resection. Wound dehiscences were minor, with
none requiring admission or debridement. Twenty patients experienced a wound infection,
but only 11% of the patients received intravenous antibiotics or required radiologic
intervention (grade 3). Twenty-five (28.7%) patients had a history of smoking, but only 9
(10.3%) smoked in the 1 month before the MILND procedure. Smoking history was
associated with a higher rate of AEs (88% vs 65%; Fisher exact test P = 0.036).
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Of the 77 procedures successfully completed by a minimally invasive approach, 16 (21%)
developed a wound infection (1 grade I, 7 grade II, 8 grade III). Prophylactic antibiotics
upon discharge were received by 23/77 (30%) of the patients. Moreover, 15/54 (28%) of the
MILND procedures not prescribed prophylactic antibiotics developed wound infections
versus 1/23 (4%) of those discharged on prophylactic antibiotics. None of the patients
converted (0/10) received prophylactic antibiotics, and 4/10 (40%) of those who converted to
an open procedure developed a wound infection (2 grade II and 2 grade III). Of the 87
patients, 21 (24%) had at least 1 wound-related event (wound infection, wound dehiscence,
or skin injury/necrosis). The indication for lymphadenectomy did not seem to influence the
wound complication rate. A wound-related AE was observed in 3/22 (14%) of those with
clinical nodal disease and 18/65 (28%) of those with a positive SLN (P = 0.183) (chi-square
test, P = 0.183).
The number of drain-days was available for 80 patients. The median number of drain-days
was 27.6 (n = 72, IQR 19–34) among those who completed MILND and 24.6 (n = 8, IQR
13–28.5) among those who converted to open procedure. Patients whose indication for an
inguinal lymphadenectomy was clinical nodal disease had their drains in place longer
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(median 30, IQR 27–38) than patients undergoing a MILND for a positive SLN (median
24.5, IQR 17–32, Kruskal-Wallis P = 0.027). The number of drain-days did not correlate
with either wound infection, seroma (Kruskal-Wallis P = 0.55 and P = 0.21, respectively), or
whether a Harmonic Scalpel or LigaSure was used (Kruskal-Wallis P = 0.21). A fibrin
sealant was used in 15 (17.4%) cases and did not correlate with drain-days or postoperative
seroma. Energy source utilized was not randomized and purely a surgeon choice. Harmonic
scalpel was used in 69 cases (80%), LigaSure in 15 (17.4%), both in 2 (2.3%) cases, and the
data are missing for 1 case. There were 10 (14.5%) cases of seroma in the Harmonic scalpel
group and none in the LigaSure group, though this was not significant (P = 0.12). The
median operative times were on average 12 minutes shorter and drain-days 2 days longer in
the LigaSure group; however, the type of energy source used did not correlate with either of
these outcomes.

Author Manuscript

Wound infection rate, operative time, and number of lymph nodes identified were not found
to differ with respect to BMI. However, increasing BMI seemed to be associated with an
increased rate of lymphedema; for BMI <25, 25 to 30, and >30, the lymphedema rates were
40%, 48%, and 72%, respectively. Among the 83 patients evaluated for lymphedema on day
30, lymphedema rates were somewhat higher among those with BMI >30 than those with
BMI ≤30 (63.3% vs 41.1%; Fisher exact test P = 0.07). Of these 83 patients, 49 (59%) were
re-evaluated at day 90, where lymphedema persisted in 11 (22%) and an additional 3 (6%)
cases were reported.

DISCUSSION

Author Manuscript

In a multi-institutional, prospective trial evaluating a structured training program for
MILND, the number of lymph nodes pathologically identified met the current oncologic
guidelines and published benchmarks. The median number of lymph nodes pathologically
identified (SLNB + MILND) was 12 (IQR 8, 14). These early cases in a surgeon's
experience utilizing a new procedure were also associated with low morbidity and short
hospital LOS.
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The recommended minimum lymph node count for an inguinal lymphadenectomy published
in the literature varies from 5 to 10.19–24 Two studies arrived at a minimum number of 8 and
10 in an evidence-based manner based on the risk of understaging, regional recurrence,
and/or overall survival.20,23 Galliot-Repkat et al set a benchmark at 10, based on survival
data in melanoma patients after lymphadenectomies and Bilimoria et al also used 10 as a
threshold for quality, but these models did not differentiate between the regional nodal
basins.21,25 The median number of lymph nodes pathologically identified in our study of
newly trained surgeons was 12. For the cases that were completed via a minimally invasive
approach, 68% had 10 or more lymph nodes and only 20% had less than 8 total inguinal
nodes. This compares favorably with the Melanoma Institute of Australia's (MIAs) finding,
as shown in Table 2, with a mean of 12.1% and 90% of their inguinal lymphadenectomy
cases having at least 8 lymph nodes examined.26 Our methodology was also similar to that
of MIA in including prior SLNB lymph nodes into the count of total regional nodes
examined. Unlike their study, we did not include prior lymph nodes removed via an
excisional biopsy. Comparing our study with multi-institutional trials of the open procedure
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is probably the best comparison for the adequacy of the lymph node count. The mean lymph
node count for inguinal lymphadenectomies was 11 in both the MSLT-I trial (Mark Faries,
personal communication) and the Sunbelt Melanoma Trial27 (Table 2).
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Minimally invasive lymph node dissection has been shown to have favorable short-term
outcomes compared with the open approach, and this is supported by the current multiinstitutional study. Although 71% of patients enrolled suffered an AE, we were probably
overly stringent in documenting all events prospectively, as noted by grade 1 fatigue, contact
dermatitis, and an episode of syncope all being counted as AEs. Many of these events would
likely not have been identified in a retrospective review, or counted as a complication in
national registries or prospective trials. Excluding acute lower-extremity edema (3 cases), 20
(23%) patients suffered grade 3 AEs, including 10 patients who received intravenous
antibiotics, 6 seromas that required a drain to be replaced, 2 skin injuries that required
debridement, 1 patient requiring a blood transfusion, and 1 femoral nerve injury. The
complication rate reported in this study would be expected to decrease as more experience is
gained with performing this procedure. The learning curve for this trial has recently been
reported,28 and how baseline laparoscopic skills influenced outcomes will be the subject of
future publications from this study. Unlike prior studies which have demonstrated decreased
morbidity when an inguinal lymphadenectomy is performed for clinical nodal disease as
opposed to microscopic disease, that is, positive SLN,8,29 this was not our experience. The
drain-days were on average longer for those with clinical disease, but the seroma rate and
wound complication rate were not statistically different.
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The current Centers for Disease Control (CDC) definition of postoperative wound infections
does not include cellulitis treated with oral outpatient antibiotics, secondary to this being
very subjective and unreliable. In our study, only 11% of patients experienced a grade 3
wound infection, 8/77 (10%) completed via MILND, and 2/10 (20%) of those converted. We
noticed a lower infection rates in those discharged on prophylactic antibiotics. This care
management was at the discretion of the treating surgeon, and this finding is worth further
exploration. The infection rate reported in this study of inguinal lymph node dissections
compares very favorably with the literature for the open procedure, as does our wound
dehiscence and seroma rates (Fig. 2). Coit et al reported a 64% in hospital wound
complication rate. Overall, 45% of patients suffered a major wound complication including
frank purulent drainage or wound dehiscence.4 This high complication rate is similar to that
documented in other prospective studies.3,5 Wound dehiscence occurred in 45% of patients
in the study by Serpell et al,5 and 53% in the trial by Chang et al.3 It should also be
appreciated that the significance of a wound dehiscence has a markedly different
connotation for an open inguinal lymphadenectomy compared with a 1 cm trocar site
incision. In the MD Anderson series, a major wound dehiscence, defined as the requirement
for a vacuum-assisted wound device, occurred in 13% of cases.3 Three of the patients in the
current study developed a seroma that was observed, 3 were aspirated, and 6 had a second
drain placed. These seroma rates compare favorably with the open procedure as shown
Figure 2. Martin et al have published the only prospective review of the perioperative
complications after MILND. They also included in their definition of a wound infection any
use of antibiotic. In 40 patients, their overall complication rate was 47.5%; lymphedema was
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not recorded, but their infection (40%), seroma (22.5%), and flap necrosis rate (2.5%) were
similar to ours.13
Retrospective studies have also demonstrated a lower complication rate and shorter hospital
LOS for MILND compared with an open approach.12,13,30 A comparison of LOS between
our contemporary study and historical references of the open trials is not appropriate,
because LOS has decreased over time for a multitude of reasons. This is reflected in the
Memorial Sloan Kettering study published in 1991 in which the mean LOS was 7 days for
those without a wound complication and 13 days for those experiencing a wound
complication,4 and in the Serpell et al5 study in which patients were kept in the hospital until
the drain was removed.
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Lymphedema is the most dreaded long-term complication of inguinal lymphadenectomy.
The incidence and potential quality of life impact of lymphedema in the lower extremity
after a groin dissection is magnified over that commonly experienced in the arm after an
axillary lymph node dissection. Chang et al3 reported a 3-month incidence of 45% for open
groin dissections based on 2 prospective studies. Lower-extremity lymphedema often occurs
early, but may undergo reduction or disappear completely after 6 months,31 whereas others
have reported a mean time to maximum lymphedema of 14.7 months.32 Spillane et al33
reported an incidence of approximately 16% in patients seen at least 6 months after their
inguinal lymphadenectomy. Forty-one percent of patients enrolled in our trial developed
lymphedema (17 grade 1, 22 grade 2, and 2 grade 3) within 30 days of MILND. Fifty-four
percent of patients enrolled in this trial developed lymphedema at some time, with only 3%
grade 3. Reporting the incidence of worst outcome (54%) may not be reliable as only about
half of the patients returned for 90-day follow-up. Acute postoperative limb volume changes
seem common after this procedure; however, it is not clear at this time what the long-term
incidence of lymphedema will be and how that will compare with the open procedure.
Minimally invasive lymph node dissection is a novel approach to inguinal lymph node
staging and treatment.11,12 We report an excellent safety profile and lymph node count from
a prospective multi-institutional trial for this procedure. These results were obtained after a
rigorous training program of surgeons with a high-volume melanoma practice and extensive
experience with open inguinal lymphadenectomies. We have established that high-volume
melanoma surgeons can safely and adequately perform MILND after a structured training
program.
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FIGURE 1.

Histogram, which visually depicts the distribution of the number of LNs pathologically
identified for the cases completed via a minimally invasive approach (N = 77). LN indicates
lymph node.
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FIGURE 2.

Comparison of complications from this prospective study versus prospective open trials. *In
the study by Coit et al, wound infections and wound dehiscences were grouped.
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TABLE 1

Author Manuscript

List of Complications of All Attempted MILND Procedures on an Intent-to-treat Basis
Maximum Grade Complications (N = 87)
Complications

Grade 1

Grade 2

Lymphedema

18 (21%)
1 (1%)

Wound infection
Hemorrhage

Grade 3

Total

26 (30%)

3 (3%)

47 (54%)

9 (10%)

10 (11%)

20 (23%)

10 (11%)

2 (2%)

1 (1%)

13 (15%)

Seroma

3 (3%)

3 (3%)

6 (7%)

12 (14%)

Skin injury/necrosis

1 (1%)

2 (2%)

3 (3%)

Wound dehiscence

1 (1%)

1 (1%)

Other

2 (2%)

1 (1%)

Total

37 (43%)

42 (49%)

Peripheral motor neuropathy

2 (2%)
1 (1%)

1 (1%)
3 (3%)

23 (26%)
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TABLE 2

Author Manuscript

Comparison of Lymph Node Count in Our Trial With the MIA Open Inguinal Lymphadenectomy Experience
and 2 Prospective Multi-institutional Trials Utilizing an Open Approach to Inguinal Lymphadenectomy
Mean

Median

Range

8 or More

11 or More

MIA25

12.1

11

3–27

90%

62%

Current study

11.6

12

3–23

80%

60%

Sunbelt26

11

—

2–37

—

—

*

—

11

—

—

—

MSLT-I

MIA indicates Melanoma Institute of Australia; MSLT-I, Melanoma Sentinel Lymph Node Trial 1.

*

Personal communication with Dr Mark Faries.
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